Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
NewsUpdated Report an error

When the Measuring Stick Moves: Biohaven, the FDA, and What It Means for SCA Patients

The FDA turned down Biohaven's troriluzole for SCA in November 2025. Biohaven says its data showed 50-70% slower progression against an outside comparison group, and the FDA's published letter says that comparison was too open to bias to show the drug works. For patients losing coordination, speech, and independence with no approved treatments, the stakes could not be higher.

Biohaven logo

At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Biohaven's leadership addressed the complete response letter for their spinocerebellar ataxia program. The discussion covered regulatory process, study design, and internal FDA dynamics. Underneath all of that, the conversation kept circling back to what matters most: the patients.

According to StatPearls (National Library of Medicine), there are more than 40 identified genetic subtypes of SCA, with SCA3 (also known as Machado-Joseph disease) being the most common, making up 25-50% of cases. The global prevalence is estimated at 1-5 per 100,000 individuals. For those affected, the disease touches every part of daily life. Walking becomes uncertain, then impossible. Speech becomes slurred, then silent. Because SCA is autosomal dominant, each child of an affected parent has a 50% chance of inheriting the same mutation.

By the numbers
40+
Genetic subtypes identified
50-70%
Slower progression Biohaven reports for [troriluzole](/drugs/troriluzole) vs an outside group, which the FDA did not accept
0
FDA-approved disease-modifying treatments
8 years
Biohaven says it worked with the FDA on this program

Biohaven CEO Vlad Coric mentioned that their data showed roughly a 70% slowing of disease progression with troriluzole (branded as VYGLXIA). If a slowing like that were confirmed in a controlled trial, it could mean more time with coordination, speech and independence. The FDA concluded the data did not establish that troriluzole works.

Why the FDA Rejected Biohaven's SCA Treatment

Coric said the complete response letter was not about safety or about the FDA suddenly finding something wrong with the data. Biohaven said the CRL, issued on November 4, 2025, cited potential bias, design flaws, lack of pre-specification and unmeasured confounding factors in its real-world evidence study, which compared treated patients with an outside natural history group.

The FDA has since published the letter itself. It says the agency raised concerns before that study began that an outside natural history comparison would likely not be enough, in part because the original placebo-controlled trial, Study 206, failed on all of its primary and secondary endpoints, and that it repeated those concerns at a later meeting. The FDA filed the application anyway, the letter says, given the seriousness and rarity of SCA. It then lists problems it found, including overlap between the sites that ran both groups (12 of 18 natural history sites), year 3 data missing for 52% of treated patients and 79% of controls, assessments up to 90 days apart, and an analysis plan drafted in 2024 with knowledge of earlier results. When timing was aligned, the FDA says, the result was no longer statistically significant. The letter calls the year 3 difference of 0.79 points on the f-SARA scale of uncertain clinical meaningfulness, and says new nonclinical studies Biohaven submitted in an amendment were not reviewed for this decision.

Coric argued that Biohaven ended up in a gray area of regulatory inconsistency. In his view, different divisions within the FDA apply different standards for rare diseases. Some groups, he said, are willing to accept smaller or less traditional evidence packages when treatment options are limited, while others apply a bar that looks more like what you would expect for common diseases with large patient populations and straightforward trial designs.

Many in the ataxia community wanted more flexibility. After the FDA refused to file the first application in 2023, more than 3,000 people answered a National Ataxia Foundation survey, and according to the foundation, 97% of respondents agreed the FDA should apply regulatory flexibility and accept the application for full review.

8 Years of SCA Clinical Development

Biohaven says it worked with the FDA for roughly 8 years with ongoing feedback and oversight. Biohaven describes the program as the first to show therapeutic potential in SCA. Its original placebo-controlled Phase 3 trial missed its main goal. Biohaven says the later real-world evidence study met its primary endpoint on the functional Scale for the Assessment and Rating of Ataxia (f-SARA) and showed statistically significant results across 9 consecutive, prespecified primary and secondary endpoints at the 3-year mark. The FDA's letter says the study's analysis plan was drafted in 2024 with knowledge of earlier results, and disputes that it was prespecified.

Over timelines like that, administrations change and review teams evolve. Coric's argument is that standards are applied unevenly. The FDA's letter says it raised its concerns about the outside comparison before the study began and repeated them later. Where standards do shift over a long program, rare disease development gets even harder, especially when there are no alternative treatments and the disease keeps progressing.

Right after the CRL, Biohaven announced it would cut its annual R&D spending by about 60%, BioSpace reported on November 5, 2025. For a company that spent nearly a decade building this program, the regulatory setback carried real consequences beyond the science.

Latest for Spinocerebellar Ataxia

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Want the next Spinocerebellar Ataxia update without checking back?

We email you when a new Spinocerebellar Ataxia trial opens or an FDA decision comes out.

You'll get trial alerts and disease updates for Spinocerebellar Ataxia, and you can turn either off anytime. We never share your email. Privacy policy

A Pattern Across Rare Disease FDA Decisions

Biohaven is not the only rare disease company to say the FDA changed course. Similar challenges played out with tabelecleucel (Ebvallo), Atara Biotherapeutics' cell therapy for EBV-positive post-transplant lymphoproliferative disease, which received a second complete response letter in January 2026. Pierre Fabre, Atara's partner and the company that held the application, said the letter was a reversal, because the FDA no longer considered the single-arm ALLELE trial it had previously accepted to be adequate. The FDA's letter said the evidence was insufficient to show effectiveness, according to BioSpace. Pierre Fabre announced on September 30, 2026 that it had resubmitted the application, and on October 14, 2026 it said the FDA had accepted it with a target action date of March 31, 2027.

These decisions affect more than timelines or valuations. They shape whether patients ever gain access to therapies that may slow decline or extend life. These companies are not talking about common diseases or cosmetic treatments. For some patients, this is life or death.

What Comes Next for Troriluzole and SCA Patients

To Biohaven's credit, the company has stayed forward-looking. It continues to advocate for SCA patients and said in November 2025 that it was formally requesting a meeting with the FDA. On October 22, 2026, Biohaven said in a company filing that the FDA had accepted a resubmitted application for review. Biohaven says the resubmission adds new positive supportive analyses, and the FDA treats it as a complete response to the 2025 letter. The FDA set a goal date in the first quarter of 2027 and plans to convene its Peripheral and Central Nervous System Drugs Advisory Committee, with no meeting date announced yet. Acceptance is not approval, and Biohaven says the goal date does not guarantee an FDA action by then, because the FDA can extend the review. Troriluzole still does not appear on Biohaven's pipeline page, and ClinicalTrials.gov still lists its expanded access program (NCT06034886) as available. An ataxia specialist told a Senate committee in February 2026 that the program was about to end, so families should confirm its status with Biohaven through a neurologist.

Meanwhile, the rest of Biohaven's portfolio continues to advance. At J.P. Morgan, the company shared early clinical results from its MoDE and TRAP degrader programs, which it said showed rapid and selective removal of disease-causing proteins and early clinical improvement in patients. These are small, early, company-reported results.

By the numbers
87%
Maximum IgG drop Biohaven reported with BHV-1300
80%+
Maximum Gd-IgA1 drop Biohaven reported after a first BHV-1400 dose ([IgA nephropathy](/trials/iga-nephropathy) program)

Biohaven reported that its BHV-1300 MoDE degrader fully suppressed disease-causing antibodies in 1 Graves' disease patient within weeks, and that BHV-1400 achieved selective lowering of the disease-causing protein in IgA nephropathy, with resolution of blood in the urine and improvement in kidney function. BHV-1300 began a Phase 3 trial in Graves' disease in June 2026 (NCT07661056), and Biohaven said on October 29, 2026 that it is on track to start a pivotal Phase 3 trial of BHV-1400 in IgA nephropathy in the fourth quarter of 2026.

It is encouraging to see real innovation continue to move forward, even when one path becomes uncertain.

Understanding Spinocerebellar Ataxia

For patients and caregivers looking to learn more

SCA is a group of inherited neurodegenerative disorders caused by genetic mutations, most commonly CAG repeat expansions, that progressively damage the cerebellum. The cerebellum is the part of the brain responsible for coordinating movement, balance, and speech.

The most common subtypes include SCA3 (25-50% of cases), SCA2 (13-18%), SCA6 (13-15%), and SCA7. Symptoms typically begin in adulthood and worsen over time: progressive loss of balance and coordination (ataxia), slurred speech (dysarthria), difficulty swallowing (dysphagia), involuntary eye movements, and in many subtypes, cognitive and mood changes.

There are currently no FDA-approved disease-modifying treatments for any form of SCA. Management is limited to physical therapy, occupational therapy, speech therapy, and assistive devices. That is what makes the pursuit of treatments like troriluzole so critical for this community.

Know someone this would help?
Get the next Spinocerebellar Ataxia update by email

One email when Spinocerebellar Ataxia trials change or an FDA decision lands. No newsletter, no spam.

You'll get, for Spinocerebellar Ataxia:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Sources

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) NDA for Spinocerebellar Ataxia
Biohaven Investor Relations · November 4, 2025
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs at the 44th Annual J.P. Morgan Healthcare Conference
Biohaven Investor Relations · January 12, 2026
NAF Statement on FDA Issuing Complete Response Letter for VYGLXIA (troriluzole)
National Ataxia Foundation
Community Response Regarding Troriluzole Delivered to FDA
National Ataxia Foundation · September 2023
Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA
Pierre Fabre Pharmaceuticals (PR Newswire) · September 30, 2026
Pierre Fabre Pharmaceuticals Statement Regarding Receipt of Complete Response Letter for Tabelecleucel Biologics License Application from the U.S. Food and Drug Administration
Pierre Fabre Pharmaceuticals (PR Newswire) · January 12, 2026
Pierre Fabre Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Pierre Fabre Pharmaceuticals (PR Newswire) · October 14, 2026
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy's Rejection
BioSpace · February 26, 2026
Complete Response Letter, NDA 210862, troriluzole capsules
U.S. Food and Drug Administration · November 4, 2025
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
BioSpace · November 5, 2025
Spinocerebellar Ataxia - StatPearls
National Library of Medicine
Spinocerebellar Ataxia (SCA): Symptoms, Causes & Types
Cleveland Clinic
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole NDA
Biohaven Investor Relations · February 2025
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
NeurologyLive · October 22, 2026
TaggedNewsFDASpinocerebellar AtaxiaBiohaven

More on Trial Friend